- Home
- / ABVC BioPharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ABVC BioPharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.7
2024-10-29
Market Capitalization
$8.8 M
2024-10-29
Revenue
$509.6 K
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|
| Revenue | 3.4K | 355.8K | 969.8K | 152.4K | 509.6K |
| Cost of goods sold | 521.0 | 5.1K | 286.4K | 302.0K | 763.0 |
| Gross profit | 2.8K | 350.7K | 683.4K | (149.6K) | 508.8K |
| Gross profit margin, % | 84.5% | 70.5% | 99.9% | ||
| General and administrative expense | 5.7M | 6.1M | 5.4M | 2.3M | |
| Operating expense total | 35.1K | 12.1M | 15.8M | 8.1M | 5.2M |
| EBIT | (32.3K) | (11.7M) | (15.1M) | (8.2M) | (4.7M) |
| EBIT margin, % | -960.7% | -1558.5% | -923.3% | ||
| Investment income | (221.9K) | ||||
| Interest income | 187.8K | 185.5K | 87.4K | ||
| Interest expense | 2.5M | 646.0 | |||
| Pre tax profit | (32.3K) | (11.2M) | (15.5M) | (10.7M) | (5.4M) |
| Income tax expense | 825.0K | 797.8K | 256.0K | (110.5K) | |
| Net Income | (32.3K) | (12.0M) | (16.3M) | (10.9M) | (5.3M) |
| EPS | (0.5) | (2.0) | (0.4) |